ZOANN DREYER to Myeloid-Lymphoid Leukemia Protein
This is a "connection" page, showing publications ZOANN DREYER has written about Myeloid-Lymphoid Leukemia Protein.
Connection Strength
0.908
-
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol. 2011 Jan 10; 29(2):214-22.
Score: 0.353
-
Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208.
Score: 0.195
-
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
Score: 0.179
-
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer. 2015 Mar; 62(3):419-26.
Score: 0.116
-
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood. 2013 Apr 04; 121(14):2689-703.
Score: 0.026
-
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012 Feb 23; 119(8):1872-81.
Score: 0.024
-
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006 Jul 15; 108(2):441-51.
Score: 0.016